NR3C1 and type 2 diabetes mellitus: To our knowledge, our work might be the first report on the regulation of GR antagonist against gluconeogenic genes in such a novel mode, which is expected to provide a new approach for developing GR modulators and highlight the potential of FX5 in the treatment of T2DM.